Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80375
Name gastroesophageal adenocarcinoma
Definition A gastroesophageal cancer that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastroesophageal cancer gastroesophageal adenocarcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ARID1A inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
PBRM1 inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02578368 Phase III Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) Recruiting 1
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA 5
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Active, not recruiting USA 0
NCT03337087 Phase Ib/II Fluorouracil + Leucovorin + MM-398 + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Recruiting USA 0
NCT03697304 Phase II BI 754091 BI 754111 Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Recruiting USA | CAN 1
NCT03783936 Phase II Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Active, not recruiting USA 0
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Recruiting USA | CAN 2
NCT03921021 Phase II OBP-301 + Pembrolizumab Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma Recruiting USA 0
NCT03929666 Phase II Cisplatin + Fluorouracil + ZW25 Capecitabine + Oxaliplatin + ZW25 Fluorouracil + Leucovorin + Oxaliplatin + ZW25 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma Recruiting USA | CAN 1
NCT04021108 Phase II Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Recruiting USA 0
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Recruiting USA 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting USA 1
NCT04150640 Phase II Fluorouracil + MM-398 + Oxaliplatin Fluorouracil + MM-398 + Oxaliplatin + Trastuzumab P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Recruiting USA 0
NCT04164979 Phase II Cabozantinib + Pembrolizumab Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma Recruiting USA 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04511039 Phase I Talazoparib + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Recruiting USA 0
NCT04522336 Phase I Docetaxel + Fluorouracil + Pembrolizumab Fluorouracil + Oxaliplatin + Pembrolizumab Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Recruiting USA 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Recruiting USA 0
NCT04662710 Phase III Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Recruiting USA | CAN 21
NCT04798781 Phase II Pembrolizumab + Telatinib Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Recruiting USA 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Recruiting USA | CAN 5
NCT05027139 Phase Ib/II ALX148 + ZW25 A Study of Zanidatamab (ZW25) With ALX148 in Patients With Advanced HER2-expressing Cancer Recruiting USA 0
NCT05041153 Phase I Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Not yet recruiting USA 0
NCT05152147 Phase III Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + ZW25 Cisplatin + Fluorouracil + Tislelizumab + ZW25 Capecitabine + Oxaliplatin + Tislelizumab + ZW25 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) Recruiting 5
NCT05153304 Phase Ib/II Ipilimumab + Nivolumab A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers Not yet recruiting USA 0